Target intelligence / Profile preview

Endomucin

Molecular classification: Type I integral membrane glycoprotein, O-glycosylated transmembrane mucin

Overview

Endomucin (EMCN) is a type I integral membrane glycoprotein primarily expressed in venous and capillary endothelial cells. It plays a crucial role in vascular protection by maintaining the endothelial glycocalyx and inhibiting leukocyte adhesion. Due to its protective role in vascular integrity, particularly in the context of diabetic retinopathy, it is being explored as a therapeutic target.

Other names: EMCN2MUC14endothelial sialomucinmucin-like sialoglycoprotein

Biological functions

Inhibits leukocyte-endothelial cell adhesionMaintains endothelial glycocalyxInterferes with assembly of focal adhesion complexesInhibits cell-extracellular matrix interactionRegulates VEGFR2 endocytosis

Disease associations

InflammationDiabetic RetinopathyVascular Disease

Beyond the preview

Go deeper on Endomucin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endomucin.

Explore the full profile